FANCM is required for the PAX3::FOXO1-driven oncogenic program in rhabdomyosarcoma
Cell Reports · 2026
DOI: 10.1016/j.celrep.2026.117960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Christopher D Delaney und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA. Hauptthemen laut MEDLINE: Forkhead Box Protein O1, PAX3 Transcription Factor, DNA Helicases, Oncogene Proteins, Fusion. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Advanced Research Projects Agency.
Abstract (Originalsprache)
Many cancers are driven by mutationally altered transcription factors (TFs) that rewire cells to an oncogenic state. Cells must activate specific mechanisms to tolerate the burden of oncogenic TF activity. To define such mechanisms, we focused on a canonical oncogenic fusion protein-driven cancer, alveolar rhabdomyosarcoma (ARMS), where the PAX3::FOXO1 fusion protein hyperactivates and mislocalizes PAX3 and FOXO1 TF functions. Employing sequential functional genomic CRISPR-Cas9 screens, we identified FANCM, a DNA translocase in the Fanconi anemia pathway, as a selective dependency in PAX3::FOXO1+ ARMS. FANCM loss reduces fusion protein levels, induces myogenic differentiation, and disrupts the PAX3::FOXO1 transcriptional program, thereby halting oncogenic proliferation. Mechanistically, FANCM depletion exacerbates replication stress (RS) and DNA damage signaling, with chromatin-associated RS enriched at PAX3::FOXO1 target gene loci, resulting in selective downregulation of the oncogenic program. CRISPR exon-tiling screens prioritized FANCM's helicase and DNA-binding domains as essential for this dependency, linking FANCM-mediated replication fork binding to sustained oncogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
- INSERM UMR 944, IRSL, St Louis Hospital, University of Paris-Cité, Paris, France.
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
- Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA.
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA; Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Advanced Research Projects Agency
- V Foundation for Cancer Research
- NIH National Institute of General Medical Sciences
- National Institutes of Health National Cancer Institute
Zitieren
APA
Delaney, C. D., Lu, M., Zimmerman, S. P., Meng, Y., Vaganay, C., Cerda-Smith, C. G., Liu, A., Hoj, J. P., Killarney, S. T., Dillon, K., Stewart, A. E., Huang, K., Caci, J. D., White, O., Puissant, A., Root, D. E., Shern, J. F., Eyler, C. E., David Chen, C. W., …, & Wood, K. C. (2026). FANCM is required for the PAX3::FOXO1-driven oncogenic program in rhabdomyosarcoma. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117960
Vancouver
Delaney CD, Lu M, Zimmerman SP, Meng Y, Vaganay C, Cerda-Smith CG, et al. FANCM is required for the PAX3::FOXO1-driven oncogenic program in rhabdomyosarcoma. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117960
BibTeX
@article{Delaney2026,
author = {Delaney, Christopher D and Lu, Min and Zimmerman, Seth P and Meng, Yingying and Vaganay, Camille and Cerda-Smith, Christian G and Liu, Annie and Hoj, Jacob P and Killarney, Shane T and Dillon, Kerry and Stewart, Amy E and Huang, Kevin and Caci, Julia D and White, Olivia and Puissant, Alexandre and Root, David E and Shern, Jack F and Eyler, Christine E and David Chen, Chun-Wei and Counter, Christopher M and Linardic, Corinne M and Zou, Lee and Wood, Kris C},
title = {FANCM is required for the PAX3::FOXO1-driven oncogenic program in rhabdomyosarcoma},
journal = {Cell Reports},
year = {2026},
doi = {10.1016/j.celrep.2026.117960}
}
EUVIMED